Mirum Pharmaceuticals, Inc. (MIRM)

Market Cap	2.40B
Revenue (ttm)	379.25M
Net Income (ttm)	-77.34M
Shares Out	49.53M
EPS (ttm)	-1.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	743,621
Open	50.48
Previous Close	50.89
Day's Range	48.24 - 50.71
52-Week Range	33.45 - 54.23
Beta	0.97
Analysts	Strong Buy
Price Target	66.22 (+36.99%)
Earnings Date	Aug 6, 2025

About MIRM

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is ap...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 18, 2019
• Employees: 322
• Stock Exchange: NASDAQ
• Ticker Symbol: MIRM
• Website: https://www.mirumpharma.com

Financial Performance

In 2024, Mirum Pharmaceuticals's revenue was $336.89 million, an increase of 80.76% compared to the previous year's $186.37 million. Losses were -$87.94 million, -46.18% less than in 2023.

Analyst Summary

According to 9 analysts, the average rating for MIRM stock is "Strong Buy." The 12-month stock price target is $66.22, which is an increase of 36.99% from the latest price.

Price Target

$66.22

(36.99% upside)

Analyst Consensus: Strong Buy